


PHARMACY POLICY STATEMENT

North Carolina Marketplace

DRUG NAME

Tecartus (Brexucabtagene Autoleucel)



For **initial**

7. National Comprehensive Cancer Network. Acute Lymphoblastic Leukemia. (Version 3.2021). https://www.nccn.org/professionals/physician_gls/pdf/all.pdf. Accessed December 29, 2021.
8. Shah BD, Ghobadi A, Oluwole OO, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. *Lancet*. 2021;398(10299):491-502. doi:10.1016/S0140-6736(21)01222-8

Effective date: 01/01/2023

Revised date: 12/29/2021